current management of multiple myeloma · dimopoulos et al. n engl j med 2016 17.3 31.5 30.1 24.7...
TRANSCRIPT
![Page 1: Current management of multiple myeloma · Dimopoulos et al. N Engl J Med 2016 17.3 31.5 30.1 24.7 23.5 11.9 ... MHC LA-4 80 86 T cell 28 TCR Ipilimumab* Tremelimumab 27 70 ... Neoantigens](https://reader036.vdocument.in/reader036/viewer/2022071215/6044e58f76dade0f767eb437/html5/thumbnails/1.jpg)
Current management of
multiple myeloma
Jorge J. Castillo, MD Assistant Professor of Medicine
Harvard Medical School [email protected]
![Page 2: Current management of multiple myeloma · Dimopoulos et al. N Engl J Med 2016 17.3 31.5 30.1 24.7 23.5 11.9 ... MHC LA-4 80 86 T cell 28 TCR Ipilimumab* Tremelimumab 27 70 ... Neoantigens](https://reader036.vdocument.in/reader036/viewer/2022071215/6044e58f76dade0f767eb437/html5/thumbnails/2.jpg)
Multiple myeloma
• MM is a plasma cell
neoplasm characterized
by the accumulation of
malignant plasma cells
in the bone marrow
producing a monoclonal
paraprotein.
• MM accounts for 10%
of all hematologic
malignancies.
• Risk factors
– MGUS (1% per year)
– Age: median 66 years
– Sex: Male > female
– Race: blacks > whites >
Asians/Hispanics
– Obesity
![Page 3: Current management of multiple myeloma · Dimopoulos et al. N Engl J Med 2016 17.3 31.5 30.1 24.7 23.5 11.9 ... MHC LA-4 80 86 T cell 28 TCR Ipilimumab* Tremelimumab 27 70 ... Neoantigens](https://reader036.vdocument.in/reader036/viewer/2022071215/6044e58f76dade0f767eb437/html5/thumbnails/3.jpg)
Myeloma subtypes
Castillo. CPPOP 2016
![Page 4: Current management of multiple myeloma · Dimopoulos et al. N Engl J Med 2016 17.3 31.5 30.1 24.7 23.5 11.9 ... MHC LA-4 80 86 T cell 28 TCR Ipilimumab* Tremelimumab 27 70 ... Neoantigens](https://reader036.vdocument.in/reader036/viewer/2022071215/6044e58f76dade0f767eb437/html5/thumbnails/4.jpg)
Diagnosis of myeloma
• Clonal bone marrow
plasma cells greater
than or equal to 10%
OR
• Biopsy-proven bone or
soft tissue
plasmacytoma
• Hypercalcemia: serum calcium
>11 mg/dL
• Renal insufficiency: creatinine
clearance <40 mL/min or
serum creatinine >2 mg/dL
• Anemia: hemoglobin <10 g/dL
• Bone lesions: osteolytic
lesions on radiographs, CT,
PET/CT, or MRI
Rajkumar et al. Lancet Oncol 2014
![Page 5: Current management of multiple myeloma · Dimopoulos et al. N Engl J Med 2016 17.3 31.5 30.1 24.7 23.5 11.9 ... MHC LA-4 80 86 T cell 28 TCR Ipilimumab* Tremelimumab 27 70 ... Neoantigens](https://reader036.vdocument.in/reader036/viewer/2022071215/6044e58f76dade0f767eb437/html5/thumbnails/5.jpg)
Diagnosis of myeloma
![Page 6: Current management of multiple myeloma · Dimopoulos et al. N Engl J Med 2016 17.3 31.5 30.1 24.7 23.5 11.9 ... MHC LA-4 80 86 T cell 28 TCR Ipilimumab* Tremelimumab 27 70 ... Neoantigens](https://reader036.vdocument.in/reader036/viewer/2022071215/6044e58f76dade0f767eb437/html5/thumbnails/6.jpg)
Diagnostic update
• The following represent an 80% risk of developing
active MM within 2 years and should be considered
active MM:
– Clonal bone marrow plasma cell involvement greater than or
equal to 60%
– Serum FLC ratio greater than or equal to 100; kappa:lambda
in kappa-restricted myeloma or lambda:kappa in lambda-
restricted myeloma
– Greater than 1 focal lesion on MRI
Rajkumar et al. Lancet Oncol 2014
![Page 7: Current management of multiple myeloma · Dimopoulos et al. N Engl J Med 2016 17.3 31.5 30.1 24.7 23.5 11.9 ... MHC LA-4 80 86 T cell 28 TCR Ipilimumab* Tremelimumab 27 70 ... Neoantigens](https://reader036.vdocument.in/reader036/viewer/2022071215/6044e58f76dade0f767eb437/html5/thumbnails/7.jpg)
Improved survival in patients with myeloma
Kumar et al. Blood 2008
Kumar et al. Leukemia 2014
![Page 8: Current management of multiple myeloma · Dimopoulos et al. N Engl J Med 2016 17.3 31.5 30.1 24.7 23.5 11.9 ... MHC LA-4 80 86 T cell 28 TCR Ipilimumab* Tremelimumab 27 70 ... Neoantigens](https://reader036.vdocument.in/reader036/viewer/2022071215/6044e58f76dade0f767eb437/html5/thumbnails/8.jpg)
Greipp et al. J Clin Oncol 2005
![Page 9: Current management of multiple myeloma · Dimopoulos et al. N Engl J Med 2016 17.3 31.5 30.1 24.7 23.5 11.9 ... MHC LA-4 80 86 T cell 28 TCR Ipilimumab* Tremelimumab 27 70 ... Neoantigens](https://reader036.vdocument.in/reader036/viewer/2022071215/6044e58f76dade0f767eb437/html5/thumbnails/9.jpg)
Palumbo et al. J Clin Oncol 2015
![Page 10: Current management of multiple myeloma · Dimopoulos et al. N Engl J Med 2016 17.3 31.5 30.1 24.7 23.5 11.9 ... MHC LA-4 80 86 T cell 28 TCR Ipilimumab* Tremelimumab 27 70 ... Neoantigens](https://reader036.vdocument.in/reader036/viewer/2022071215/6044e58f76dade0f767eb437/html5/thumbnails/10.jpg)
10
Timeline of Advances in Multiple Myeloma Through 2015
![Page 11: Current management of multiple myeloma · Dimopoulos et al. N Engl J Med 2016 17.3 31.5 30.1 24.7 23.5 11.9 ... MHC LA-4 80 86 T cell 28 TCR Ipilimumab* Tremelimumab 27 70 ... Neoantigens](https://reader036.vdocument.in/reader036/viewer/2022071215/6044e58f76dade0f767eb437/html5/thumbnails/11.jpg)
Mechanism of action of proteasome inhibitors
![Page 12: Current management of multiple myeloma · Dimopoulos et al. N Engl J Med 2016 17.3 31.5 30.1 24.7 23.5 11.9 ... MHC LA-4 80 86 T cell 28 TCR Ipilimumab* Tremelimumab 27 70 ... Neoantigens](https://reader036.vdocument.in/reader036/viewer/2022071215/6044e58f76dade0f767eb437/html5/thumbnails/12.jpg)
Mechanism of action of immunomodulators
Van de Donk et al. Cancer Managem Res 2012
![Page 13: Current management of multiple myeloma · Dimopoulos et al. N Engl J Med 2016 17.3 31.5 30.1 24.7 23.5 11.9 ... MHC LA-4 80 86 T cell 28 TCR Ipilimumab* Tremelimumab 27 70 ... Neoantigens](https://reader036.vdocument.in/reader036/viewer/2022071215/6044e58f76dade0f767eb437/html5/thumbnails/13.jpg)
Mechanism of action of monoclonal antibodies
Van de Donk et al. Blood 2016
![Page 14: Current management of multiple myeloma · Dimopoulos et al. N Engl J Med 2016 17.3 31.5 30.1 24.7 23.5 11.9 ... MHC LA-4 80 86 T cell 28 TCR Ipilimumab* Tremelimumab 27 70 ... Neoantigens](https://reader036.vdocument.in/reader036/viewer/2022071215/6044e58f76dade0f767eb437/html5/thumbnails/14.jpg)
Treatment for myeloma - frontline
![Page 15: Current management of multiple myeloma · Dimopoulos et al. N Engl J Med 2016 17.3 31.5 30.1 24.7 23.5 11.9 ... MHC LA-4 80 86 T cell 28 TCR Ipilimumab* Tremelimumab 27 70 ... Neoantigens](https://reader036.vdocument.in/reader036/viewer/2022071215/6044e58f76dade0f767eb437/html5/thumbnails/15.jpg)
Treatment for myeloma - frontline
![Page 16: Current management of multiple myeloma · Dimopoulos et al. N Engl J Med 2016 17.3 31.5 30.1 24.7 23.5 11.9 ... MHC LA-4 80 86 T cell 28 TCR Ipilimumab* Tremelimumab 27 70 ... Neoantigens](https://reader036.vdocument.in/reader036/viewer/2022071215/6044e58f76dade0f767eb437/html5/thumbnails/16.jpg)
Attal et al. N Engl J Med 2017
![Page 17: Current management of multiple myeloma · Dimopoulos et al. N Engl J Med 2016 17.3 31.5 30.1 24.7 23.5 11.9 ... MHC LA-4 80 86 T cell 28 TCR Ipilimumab* Tremelimumab 27 70 ... Neoantigens](https://reader036.vdocument.in/reader036/viewer/2022071215/6044e58f76dade0f767eb437/html5/thumbnails/17.jpg)
Moreau et al. Blood 2016
![Page 18: Current management of multiple myeloma · Dimopoulos et al. N Engl J Med 2016 17.3 31.5 30.1 24.7 23.5 11.9 ... MHC LA-4 80 86 T cell 28 TCR Ipilimumab* Tremelimumab 27 70 ... Neoantigens](https://reader036.vdocument.in/reader036/viewer/2022071215/6044e58f76dade0f767eb437/html5/thumbnails/18.jpg)
Lenalidomide (n=306)
Placebo (n=302)
Hematologic cancers
13 (4%) 5 (2%)
Solid tumors 10 (3%) 4 (1%) Nonmelanoma skin cancers
5 (2%) 3 (1%)
Total 32 (9%) 12 (4%) Attal et al. N Engl J Med 2012
![Page 19: Current management of multiple myeloma · Dimopoulos et al. N Engl J Med 2016 17.3 31.5 30.1 24.7 23.5 11.9 ... MHC LA-4 80 86 T cell 28 TCR Ipilimumab* Tremelimumab 27 70 ... Neoantigens](https://reader036.vdocument.in/reader036/viewer/2022071215/6044e58f76dade0f767eb437/html5/thumbnails/19.jpg)
Lenalidomide (n=231)
Placebo (n=229)
Hematologic cancers
8 (3%) 1 (0.4%)
Solid tumors 10 (4%) 5 (2%) Nonmelanoma skin cancers
4 (2%) 3 (1.3%)
Total 22 (9%) 12 (5%)
McCarthy et al. N Engl J Med 2012
![Page 20: Current management of multiple myeloma · Dimopoulos et al. N Engl J Med 2016 17.3 31.5 30.1 24.7 23.5 11.9 ... MHC LA-4 80 86 T cell 28 TCR Ipilimumab* Tremelimumab 27 70 ... Neoantigens](https://reader036.vdocument.in/reader036/viewer/2022071215/6044e58f76dade0f767eb437/html5/thumbnails/20.jpg)
Treatment for myeloma - relapsed
![Page 21: Current management of multiple myeloma · Dimopoulos et al. N Engl J Med 2016 17.3 31.5 30.1 24.7 23.5 11.9 ... MHC LA-4 80 86 T cell 28 TCR Ipilimumab* Tremelimumab 27 70 ... Neoantigens](https://reader036.vdocument.in/reader036/viewer/2022071215/6044e58f76dade0f767eb437/html5/thumbnails/21.jpg)
Dimopoulos et al. Lancet Oncol 2016
![Page 22: Current management of multiple myeloma · Dimopoulos et al. N Engl J Med 2016 17.3 31.5 30.1 24.7 23.5 11.9 ... MHC LA-4 80 86 T cell 28 TCR Ipilimumab* Tremelimumab 27 70 ... Neoantigens](https://reader036.vdocument.in/reader036/viewer/2022071215/6044e58f76dade0f767eb437/html5/thumbnails/22.jpg)
Stewart et al. N Engl J Med 2015
![Page 23: Current management of multiple myeloma · Dimopoulos et al. N Engl J Med 2016 17.3 31.5 30.1 24.7 23.5 11.9 ... MHC LA-4 80 86 T cell 28 TCR Ipilimumab* Tremelimumab 27 70 ... Neoantigens](https://reader036.vdocument.in/reader036/viewer/2022071215/6044e58f76dade0f767eb437/html5/thumbnails/23.jpg)
Moreau et al. N Engl J Med 2016
![Page 24: Current management of multiple myeloma · Dimopoulos et al. N Engl J Med 2016 17.3 31.5 30.1 24.7 23.5 11.9 ... MHC LA-4 80 86 T cell 28 TCR Ipilimumab* Tremelimumab 27 70 ... Neoantigens](https://reader036.vdocument.in/reader036/viewer/2022071215/6044e58f76dade0f767eb437/html5/thumbnails/24.jpg)
Dimopoulos et al. N Engl J Med 2016
17.3
31.5
30.1
24.7
23.5 11.9
22.6
9.1
0.
25.
50.
75.
100.
DRd… Rd…
sCRCRVGPRPR
≥VGPR:
76%c
ORR = 77%b
≥VGPR: 46%
≥CR:
46%c ≥CR:
21%
ORR = 93%b
P <0.0001
OR
R, %
![Page 25: Current management of multiple myeloma · Dimopoulos et al. N Engl J Med 2016 17.3 31.5 30.1 24.7 23.5 11.9 ... MHC LA-4 80 86 T cell 28 TCR Ipilimumab* Tremelimumab 27 70 ... Neoantigens](https://reader036.vdocument.in/reader036/viewer/2022071215/6044e58f76dade0f767eb437/html5/thumbnails/25.jpg)
Palumbo et al. N Engl J Med 2016
![Page 26: Current management of multiple myeloma · Dimopoulos et al. N Engl J Med 2016 17.3 31.5 30.1 24.7 23.5 11.9 ... MHC LA-4 80 86 T cell 28 TCR Ipilimumab* Tremelimumab 27 70 ... Neoantigens](https://reader036.vdocument.in/reader036/viewer/2022071215/6044e58f76dade0f767eb437/html5/thumbnails/26.jpg)
Lonial et al. N Engl J Med 2016
![Page 27: Current management of multiple myeloma · Dimopoulos et al. N Engl J Med 2016 17.3 31.5 30.1 24.7 23.5 11.9 ... MHC LA-4 80 86 T cell 28 TCR Ipilimumab* Tremelimumab 27 70 ... Neoantigens](https://reader036.vdocument.in/reader036/viewer/2022071215/6044e58f76dade0f767eb437/html5/thumbnails/27.jpg)
Pomalidomide plus low-dose dexamethasone versus high-dose
dexamethasone alone for patients with relapsed and refractory
multiple myeloma (MM-003): a randomised, open-label, phase 3 trial
San Miguel et al. Lancet Oncol 2013
![Page 28: Current management of multiple myeloma · Dimopoulos et al. N Engl J Med 2016 17.3 31.5 30.1 24.7 23.5 11.9 ... MHC LA-4 80 86 T cell 28 TCR Ipilimumab* Tremelimumab 27 70 ... Neoantigens](https://reader036.vdocument.in/reader036/viewer/2022071215/6044e58f76dade0f767eb437/html5/thumbnails/28.jpg)
28
Selected Phase III Trials in Relapsed Disease
Name of trial No. prior lines Arm N PFS (months)
ORR ≥VGPR ≥CR
ENDEAVOR 1-3 Kd 464 18.7 77% 54% 13%
Vd 465 9.4 63% 29% 6%
TOURMALINE-MM1 1-3 IRd 360 20.6 78% 48% 12%
Rd 362 14.7 72% 39% 7%
ELOQUENT-2 1-3 Elo-Rd 321 19.4 79% 33% 4%
Rd 325 14.9 66% 28% 7%
ASPIRE 1-3 KRd 396 26.3 87% 70% 32%
Rd 396 17.6 67% 40% 9%
PANORAMA 1 1-3 Pano-Vd 387 12.0 61% 11%
Vd 381 8.0 55% 6%
NIMBUS (MM-003) ≥2§ Pd 302 4.0 31% 6% 1%
D 153 1.9 10% 1% 0%
CASTOR ≥1 Vd-dara 251 NE 83% 59% 19%
Vd 247 7.2 63% 29% 9%
POLLUX ≥1 Rd-dara 286 NE 93% 76% 43%
Rd 283 18.4 76% 44% 19%
![Page 29: Current management of multiple myeloma · Dimopoulos et al. N Engl J Med 2016 17.3 31.5 30.1 24.7 23.5 11.9 ... MHC LA-4 80 86 T cell 28 TCR Ipilimumab* Tremelimumab 27 70 ... Neoantigens](https://reader036.vdocument.in/reader036/viewer/2022071215/6044e58f76dade0f767eb437/html5/thumbnails/29.jpg)
Management issues
Proteasome inhibitors Immunomodulators
• Full-dose aspirin for
thrombosis prophylaxis
• Risk of secondary cancers
Daratumumab
• Zoster prophylaxis
• False positive Coombs
• SPEP interference
• Flow interference
• Zoster prophylaxis
• Subcutaneous bortezomib
is preferred
• Carfilzomib can cause
cardiac and pulmonary
toxicity in elderly patients
Elotuzumab
• SPEP interference
![Page 30: Current management of multiple myeloma · Dimopoulos et al. N Engl J Med 2016 17.3 31.5 30.1 24.7 23.5 11.9 ... MHC LA-4 80 86 T cell 28 TCR Ipilimumab* Tremelimumab 27 70 ... Neoantigens](https://reader036.vdocument.in/reader036/viewer/2022071215/6044e58f76dade0f767eb437/html5/thumbnails/30.jpg)
La Huerta et al. J Clin Oncol 2017
![Page 31: Current management of multiple myeloma · Dimopoulos et al. N Engl J Med 2016 17.3 31.5 30.1 24.7 23.5 11.9 ... MHC LA-4 80 86 T cell 28 TCR Ipilimumab* Tremelimumab 27 70 ... Neoantigens](https://reader036.vdocument.in/reader036/viewer/2022071215/6044e58f76dade0f767eb437/html5/thumbnails/31.jpg)
PFS According to MRD Status at 10–5
CASTOR POLLUX
Patients
pro
gre
ssio
n fre
e a
nd a
live
(%)
0
20
40
60
80
100
0 3 6 9 12 15 18 24
Vd MRD negative
DVd MRD negative
Vd MRD positive
DVd MRD positive
Patients at risk
Months
21
6
26
241
225
6
26
176
189
6
26
123
172
5
26
68
134
3
15
20
76
2
7
7
26
0
1
0
4
0
0
0
1
0
0
0
0
Patients
pro
gre
ssio
n fre
e a
nd a
live
(%)
0
20
40
60
80
100
0 3 6 9 12 15 21 27
Rd MRD negative
DRd MRD negative
Rd MRD positive
DRd MRD positive
Patients at risk
Months
24
16
71
267
215
16
71
233
195
16
71
190
178
15
70
166
167
15
66
144
161
12
57
120
137
0
6
5
9
0
0
0
1
0
0
0
0
18
10
28
38
54
Rd MRD–
DRd MRD–
DRd MRD+
Rd MRD+
Vd MRD–
DVd MRD–
DVd MRD+
Vd MRD+
Usmani, et al. ASH 2016; 653:1151
Mateos, et al. ASH 2016; 653:1150
![Page 32: Current management of multiple myeloma · Dimopoulos et al. N Engl J Med 2016 17.3 31.5 30.1 24.7 23.5 11.9 ... MHC LA-4 80 86 T cell 28 TCR Ipilimumab* Tremelimumab 27 70 ... Neoantigens](https://reader036.vdocument.in/reader036/viewer/2022071215/6044e58f76dade0f767eb437/html5/thumbnails/32.jpg)
Barlogie et al. Blood 2014
![Page 33: Current management of multiple myeloma · Dimopoulos et al. N Engl J Med 2016 17.3 31.5 30.1 24.7 23.5 11.9 ... MHC LA-4 80 86 T cell 28 TCR Ipilimumab* Tremelimumab 27 70 ... Neoantigens](https://reader036.vdocument.in/reader036/viewer/2022071215/6044e58f76dade0f767eb437/html5/thumbnails/33.jpg)
Venetoclax – Mechanism of Action
Roberts et al. N Engl J Med 2015
Punnoose et al. Mol Cancer Ther 2016
• Anti-apoptotic proteins BCL-2 and MCL-1 promote multiple myeloma (MM) cell survival
• Venetoclax is a selective, orally available small molecule BCL-2 inhibitor1 and bortezomib can indirectly inhibit MCL-1
• Venetoclax enhanced bortezomib activity in vitro and in vivo2
![Page 34: Current management of multiple myeloma · Dimopoulos et al. N Engl J Med 2016 17.3 31.5 30.1 24.7 23.5 11.9 ... MHC LA-4 80 86 T cell 28 TCR Ipilimumab* Tremelimumab 27 70 ... Neoantigens](https://reader036.vdocument.in/reader036/viewer/2022071215/6044e58f76dade0f767eb437/html5/thumbnails/34.jpg)
• N = 66
• Median age: 64 y
• Median of 3 prior lines of therapy
All patients 66 67
Not refractory to bortezomib 39 90
Bortezomib-refractory 26 31
1 to 3 prior therapies 37 89
4 to 6 prior therapies 29 38
Bcl-2 high 18 94
Bcl-2 low 27 59
ORR, %
Moreau et al. ASH 2016
n
• Venetoclax/bortezomib/dexamethasone was well tolerated, no MTD
• Clinical benefit was higher in patients with fewer lines of therapy,
patients who were not bortezomib-refractory, and patients who had high
Bcl-2 expression
Venetoclax + Bortezomib + Dexamethasone
![Page 35: Current management of multiple myeloma · Dimopoulos et al. N Engl J Med 2016 17.3 31.5 30.1 24.7 23.5 11.9 ... MHC LA-4 80 86 T cell 28 TCR Ipilimumab* Tremelimumab 27 70 ... Neoantigens](https://reader036.vdocument.in/reader036/viewer/2022071215/6044e58f76dade0f767eb437/html5/thumbnails/35.jpg)
Selinexor: A new class of drug
![Page 36: Current management of multiple myeloma · Dimopoulos et al. N Engl J Med 2016 17.3 31.5 30.1 24.7 23.5 11.9 ... MHC LA-4 80 86 T cell 28 TCR Ipilimumab* Tremelimumab 27 70 ... Neoantigens](https://reader036.vdocument.in/reader036/viewer/2022071215/6044e58f76dade0f767eb437/html5/thumbnails/36.jpg)
Selinexor – STORM Trial Quad and Penta Refractory
Vogl et al. ASH 2016
STORM Trial
N=78
Response
VGPR 5 %
PR 15 %
MR 13 %
Patient
Characteristics
Sel Dex
Quad Refr
Sel Dex
Penta Refr Sel VD Sel KD Sel PomD
Patients Enrolled 48 31 33 22 20
Median Priors
(range) 7 (3 – 16) 7 (5 – 17) 4 (1 – 11) 4 (2 – 10) 5 (2 – 9)
ORR 21% 20% 77% 63% 60%
CBR 29% 40% 91% 84% 73%
![Page 37: Current management of multiple myeloma · Dimopoulos et al. N Engl J Med 2016 17.3 31.5 30.1 24.7 23.5 11.9 ... MHC LA-4 80 86 T cell 28 TCR Ipilimumab* Tremelimumab 27 70 ... Neoantigens](https://reader036.vdocument.in/reader036/viewer/2022071215/6044e58f76dade0f767eb437/html5/thumbnails/37.jpg)
Antigen Presenting Cell
MHC
CTL
A-4
CD
80
C
D8
6
T cell
TCR CD
28
Ipilimumab* Tremelimumab
CD
27
C
D7
0
PD
L1
PD
L2
Nivolumab* Pembrolizumab* Pidilizumab
Durvalumab Atezolizumab* MSB0010718C BMS-936559
*US Food and Drug Administration
(FDA) Approved
Predictors of Clinical Activity
(based on solid tumor
experience)
• Tumor antigen–specific T cells
• Neoantigens
• Shared antigens
• Antigen presentation
• Evidence of immune
recognition
• Adaptive resistance
• “Target expression”
Checkpoint inhibitors
Leshokin et al. IMW New Delhi 2017
![Page 38: Current management of multiple myeloma · Dimopoulos et al. N Engl J Med 2016 17.3 31.5 30.1 24.7 23.5 11.9 ... MHC LA-4 80 86 T cell 28 TCR Ipilimumab* Tremelimumab 27 70 ... Neoantigens](https://reader036.vdocument.in/reader036/viewer/2022071215/6044e58f76dade0f767eb437/html5/thumbnails/38.jpg)
Pembrolizumab + RD for Relapsed/ Refractory MM
Best Overall Response n (%)
Efficacy Population†
(n = 40)
Lenalidomide
Refractory
(n = 29)
ORR 20 (50) 11 (38)
Stringent CR (sCR) 1 (3) 1 (3)
Very good PR (VGPR) 5 (13) 3 (10)
PR 14 (35) 7 (24)
SD 19 (48) 17 (59)
Disease control rate (CR + PR + SD) 39 (98) 28 (97)
Progressive disease (PD) 1 (3) 1 (3)
Mateos et al. J Clin Oncol 2016
• 11 patients NE by central review
• 3 discontinued within cycle 1 for reasons other than PD (2 no
treatment assessments and 1 SD by investigator)
• 8 inadequate myeloma data for response assessment (5 PD
and 3 SD by investigator)
![Page 39: Current management of multiple myeloma · Dimopoulos et al. N Engl J Med 2016 17.3 31.5 30.1 24.7 23.5 11.9 ... MHC LA-4 80 86 T cell 28 TCR Ipilimumab* Tremelimumab 27 70 ... Neoantigens](https://reader036.vdocument.in/reader036/viewer/2022071215/6044e58f76dade0f767eb437/html5/thumbnails/39.jpg)
Future: CAR T-cells
Autologous T-cells engineered to express a T-cell receptor that specifically
targets an antigen (BCMA, CD38) on the myeloma cells
![Page 40: Current management of multiple myeloma · Dimopoulos et al. N Engl J Med 2016 17.3 31.5 30.1 24.7 23.5 11.9 ... MHC LA-4 80 86 T cell 28 TCR Ipilimumab* Tremelimumab 27 70 ... Neoantigens](https://reader036.vdocument.in/reader036/viewer/2022071215/6044e58f76dade0f767eb437/html5/thumbnails/40.jpg)
Future: CAR-T Cell for Refractory MM
Lin et al. EORTC-NCI-AACR 2016
![Page 41: Current management of multiple myeloma · Dimopoulos et al. N Engl J Med 2016 17.3 31.5 30.1 24.7 23.5 11.9 ... MHC LA-4 80 86 T cell 28 TCR Ipilimumab* Tremelimumab 27 70 ... Neoantigens](https://reader036.vdocument.in/reader036/viewer/2022071215/6044e58f76dade0f767eb437/html5/thumbnails/41.jpg)
Conclusions
• The survival of patients with myeloma is
improving.
• Primary treatment should include RVD followed by
ASCT, if appropriate, and maintenance.
• Multiple treatment options for relapsed and/or
refractory myeloma patients.
• Venetoclax, selinexor, checkpoint inhibitors are
undergoing clinical trials.
![Page 42: Current management of multiple myeloma · Dimopoulos et al. N Engl J Med 2016 17.3 31.5 30.1 24.7 23.5 11.9 ... MHC LA-4 80 86 T cell 28 TCR Ipilimumab* Tremelimumab 27 70 ... Neoantigens](https://reader036.vdocument.in/reader036/viewer/2022071215/6044e58f76dade0f767eb437/html5/thumbnails/42.jpg)
Current management of
multiple myeloma
Jorge J. Castillo, MD Assistant Professor of Medicine
Harvard Medical School [email protected]